News FDA starts review of Regeneron's drug for rare disease FOP Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?
News Regeneron drug on track to be second FOP treatment There is only one approved drug for ultra-rare disease FOP on the market, but Regeneron is hoping to add a second.
News FDA sets new decision date for Ipsen’s FOP therapy US agency sets 23rd August deadline for palovarotene review as Ipsen files more clinical data.
News Ipsen adds Blueprint's FOP rare disease drug to pipeline for... Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a licence to develop and market a drug for the rare disease fibrodysplasia ossifican
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
